Comparative Pharmacology
Head-to-head clinical analysis: GLYCOPREP versus PORTALAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLYCOPREP versus PORTALAC.
GLYCOPREP vs PORTALAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glycopyrrolate is a competitive antagonist of acetylcholine at muscarinic receptors, thereby inhibiting the effects of parasympathetic nervous system activation. It does not cross the blood-brain barrier significantly, producing peripheral anticholinergic effects.
Lactulose is a synthetic disaccharide that is not absorbed from the gastrointestinal tract. It is metabolized by colonic bacteria to short-chain fatty acids (e.g., acetic, lactic, and formic acid), resulting in acidification of colonic contents and an increase in osmotic pressure, which stimulates bowel evacuation. In hepatic encephalopathy, acidification reduces blood ammonia levels by converting NH3 to NH4+ in the colon, inhibiting ammonia absorption.
Adults: 10 units subcutaneously 30 minutes before first meal of the day, then 5 units after each subsequent meal. Total daily dose should not exceed 30 units.
Initial: 15-30 mL (10-20 g lactulose) orally, 2-3 times daily; titrate to 2-3 soft stools daily. For acute hepatic encephalopathy: 30-45 mL (20-30 g) orally every hour until evacuation, then 3-4 times daily.
None Documented
None Documented
Terminal half-life 1.5-2 hours in adults; prolonged in renal impairment (up to 10-12 hours in anuria).
1.7-2.0 hours (terminal); clinical context: short t1/2 allows rapid dose adjustment in hepatic encephalopathy.
Primarily renal (90% unchanged) via glomerular filtration and tubular secretion; biliary/fecal <10%.
Renal: ~40% as unchanged drug; fecal: ~60% as metabolites (biliary excretion of conjugates and lactulose).
Category C
Category C
Osmotic Laxative
Osmotic Laxative